BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 263.86M | -8.78M | -35.71M | -53.47M | -88.88M |
| Total Depreciation and Amortization | 3.49M | 3.07M | 3.05M | 3.04M | 3.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 136.92M | 128.36M | 129.70M | 125.47M | 121.13M |
| Change in Net Operating Assets | -56.90M | -72.46M | -80.22M | -100.89M | -87.28M |
| Cash from Operations | 347.37M | 50.20M | 16.82M | -25.85M | -52.02M |
| Capital Expenditure | -2.47M | -2.34M | -1.06M | -1.03M | -1.12M |
| Sale of Property, Plant, and Equipment | 550.00K | 550.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -6.18M | -- | -- | -- | -- |
| Other Investing Activities | -5.59M | 89.38M | 83.56M | 51.96M | 53.72M |
| Cash from Investing | -13.69M | 87.59M | 82.51M | 50.93M | 52.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -334.76M | -137.98M | -77.68M | -1.83M | -1.70M |
| Issuance of Common Stock | 9.17M | 8.49M | 7.92M | 4.76M | 4.06M |
| Repurchase of Common Stock | -- | -581.00K | -581.00K | -581.00K | -581.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.35M | -5.93M | -5.56M | -6.54M | -7.54M |
| Cash from Financing | -349.93M | -135.99M | -75.90M | -4.18M | -5.76M |
| Foreign Exchange rate Adjustments | 1.27M | 38.00K | 1.36M | -145.00K | -936.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | -14.84M | -15.06M | -- | -- |
| Net Change in Cash | -14.99M | -13.01M | 9.72M | 20.75M | -6.12M |